At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Brentuximab vedotindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of Brentuximab Vedotin (SGN-35) in CD30-Positive Systemic Mastocytosis With or Without an Associated Hematological Clonal Non-Mast Cell Lineage Disease (AHNMD)
In Brief
A Phase 2 clinical trial evaluating Brentuximab vedotin for Aggressive Systemic Mastocytosis and 2 related conditions. Completed, enrolled 10 participants across 2 sites.
Detailed Summary
This pilot clinical trial studies brentuximab vedotin in treating patients with advanced systemic mastocytosis or mast cell leukemia. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsSeagen Inc.
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 2013
Enrollment StartSep 2013
Primary CompletionSep 2017
TodayJul 2026
First PostedMar 8, 2013
Enrollment StartSep 1, 2013
Primary CompletionSep 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 13.3 years ago
Interventions
Brentuximab vedotindrug